Latest Announcements

Virbac announces the approval of its first pharmaceutical for Swine and Cattle in the U.S. and a collaboration with Pharmgate


Westlake, TX / Wilmington, NC - Virbac is proud to announce the launch of its first product in the U.S. food production animal market with the FDA approval of Tulissin® 25 (tulathromycin injection) injectable solution and Tulissin® 100 (tulathromycin injection) injectable solution for use in cattle and swine. The product will be available in two concentrations: 100 mg/mL and 25 mg/mL to properly cover the two segments. Tulissin 100 injectable solution will be available in 500, 250, 100 and 50 mL bottles and Tulissin 25 Injectable Solution in 250 and 100 mL bottles.


Read more

Virbac Launches its C.E.T.® Dental Authority Certification Program


As an innovator in pet dental health products, Virbac recently launched its new C.E.T.® Dental Authority Certification Program, alongside Mary L. Berg, BS, RVT, RLATG, VTS (Dentistry) to help veterinarians and their healthcare teams better protect their patients' smiles. It is a free, online, self-paced program that educates users on the importance of preventative dental care in pets and how a comprehensive dental protocol can benefit both clients and clinics. The program also provides helpful tips on educating the client and facilitating those important dental discussions.

Access the Dental Authority Certification Program Here

Read more

Virbac announces the approval of Stelfonta​® (tigilanol tiglate injection)


Virbac announces the approval of Stelfonta (tigilanol tiglate injection), an innovative intratumoral injection treatment for canine mast cell tumors

Read more

Virbac completes divestment of U.S. Rights to SENTINEL​® brands to MSD Animal Health


Virbac, today announced the successful completion of its divestment of the U.S. rights to its parasiticides for dogs: SENTINEL® FLAVOR TABS® and SENTINEL® SPECTRUM® to MSD Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE:MRK). The consideration received for the transaction amounted to approximately US $400 million, subject to customary closing adjustments, settled in cash.

Read more

Virbac to divest U.S. Rights to SENTINEL​® brands to MSD Animal Health


Under the terms of this agreement, Virbac will divest a combination of titles and rights for the United States on trademarks, marketing authorizations, patents, know-how, and other assets, related to two parasiticides for dogs​: SENTINEL​® FLAVOR TABS​® and SENTINEL​®  SPECTRUM​®​. In relation with the transaction, Virbac will keep its commercial structure substantially unchanged, and will continue to manufacture SENTINEL​® SPECTRUM​®​ at its Bridgeton, Missouri site for the next ten years. 

Read more